The German Pharmaceutical Industry Association (BPI) welcomes the European Commissions revision of the EU Public Procurement Directive, as it presents a crucial opportunity to strengthen pharmaceutical supply security, support European production, and promote sustainable procurement practices. A key factor contributing to medicinal product shortagesgrowing global demandmust be acknowledged.
BGP
BPI German Pharmaceutical Industry Association
Industry association · Germany · EU Transparency Register 76399831150-89
7
positions filed
in the 326 files tracked
6
legislative files
of 326 tracked
6
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1205 trade and business associations on this site, they rank #240 by legislative files engaged — a count of participation, not a measure of influence.
3
declared lobbying FTE
self-declared
€100K+
declared costs / yr (floor)
2
EP accreditations
as declared to the register
2009
in the register since
Declares membership of
- Bundesverband der Deutschen Industrie e.V.
- Verband der Chemischen Industrie e.V.
- European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) →
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).
- Register category
- Trade and business associations
- Registered as
- Bundesverband der Pharmazeutischen Industrie e.V. (BPI e.V.)
- Head office
- Berlin, Germany
- EU office
- Brussels
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track BPI in PolicySpeak: request access →
Work at BPI German Pharmaceutical Industry Association? so we know who speaks for it.
Their record over time
BPI German Pharmaceutical Industry Association filed 7 positions between 19 Feb 2025 and 2 Jun 2026, across 6 of the 326 legislative files tracked here, attaching a full position paper 6 times.
2025 · 6 filed2026 · 1 filed
What they argued
BPI welcomes the initiative. Targeted amendments are vital to foster innovation, patient safety and sustainable competitiveness within healthcare. BPI therefore advocates for the following: Reduce administrative burdens The current re-certification and post-market surveillance requirements under MDR and IVDR impose disproportionate, duplicative burdensparticularly on SMEs and mid-caps.
BPI welcomes the European Commissions initiative, the EU Biotech Act I, which represents a crucial step towards strengthening Europes biopharmaceutical sector. It particularly supports measures to expand biopharmaceutical manufacturing capacity, reduce dependencies on critical raw materials, accelerate approval procedures, streamline regulatory pathways for advanced therapy medicinal products (ATMPs), and promote…
Biotechnology is essential to the EUs healthcare innovation, enabling advanced treatments and better outcomes for citizens. The BPI sees the EU Biotech Act as a key opportunity to accelerate this progress. For the EU to regain leadership in breakthrough therapies, it must rapidly translate scientific advances into accessible treatments through aligned legislative and non-legislative measures, such as the EU…
BPI welcomes the European Commission's proposed European Innovation Act. The Draghi report highlighted health innovation as key to Europes competitiveness, a perspective also echoed by Commission President Ursula von der Leyen in her State of the Union address, where she underscored the Unions readiness to assume global health leadership.
The German Pharmaceutical Industry Association (BPI) represents the common economic interests of its member companies, particularly in the areas of healthcare and location policy, security of supply and pharmaceutical legislation at state and federal level as well as in Europe.
Dear Sir/Madam, please find attached the opinion on the GMP guide for veterinary medicinal products. We would like to point out that the consultation deadline of only four weeks is considered insufficient to thoroughly assess all specific requirements and possible changes. In addition, the envisaged transitional period of eight months does not provide an adequate possibility for manufacturers to adapt.
Filed in German · English published by the European Commission
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
- MedTech Europe · 4 files in common
- EFPIA · 4 files in common
- EuropaBio · 4 files in common
- Cefic · 3 files in common
- Danish Industry · 3 files in common
Showing 5 of 117.
Is this your organization?
Everything on this page comes from BPI German Pharmaceutical Industry Association’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.